SynthesisInternational urology and nephrology2026
Prognosis of radical prostatectomy combined with pelvic lymph node dissection in patients with intermediate- and high-risk prostate cancer: a systematic review and single-arm meta-analysis.
Synthesis in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathy.International urology and nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe efficacy of pelvic lymph node dissection (PLND) in enhancing the prognosis of patients with intermediate- and high-risk prostate cancer (PCa) has been a subject of ongoing debate. It is noteworthy that a majority of existing studies on this topic are retrospective and have shorter follow-up durations. This meta-analysis is therefore purposed to assess the prognosis of intermediate to high-risk PCa patients who have undergone a combination of radical prostatectomy (RP) and PLND.
methodsThis study systematically searched multiple databases, including but not limited to PubMed and Web of Science, and conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant single-arm meta-analysis. Study quality was assessed using both the Cochrane risk of bias tool and ROBINS-I tool.
resultsIn our analysis, we included 18 studies that involved 3881 patients. The meta-analysis indicated that the biochemical recurrence-free survival (BRFS) rates at 2-year, 4-year, and 5-year points for intermediate- and high-risk PCa patients who received RP in conjunction with extended pelvic lymph node dissection (EPLND) were 85% (95% CI 81-88%; I
conclusionIn patients presenting with intermediate- to high-risk PCa, the combined therapeutic approach of RP with EPLND demonstrates a significant association with favorable oncological outcomes. While the intervention may be accompanied by certain AEs, it is clinically relevant to note that the majority of these complications are classified as Clavien grades 1-2. However, this conclusion still requires more high-quality research to be verified.
Indexed as
Identifiers
40788468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.